Refine
Year of publication
Language
- English (542)
Has Fulltext
- yes (542)
Is part of the Bibliography
- no (542)
Keywords
- Heavy Ion Experiments (9)
- LHC (9)
- Hadron-Hadron scattering (experiments) (6)
- ALICE experiment (4)
- ALICE (3)
- Hadron-Hadron Scattering (3)
- Heavy Ions (3)
- Heavy-ion collision (3)
- SARS-CoV-2 (3)
- pp collisions (3)
- Beauty production (2)
- COVID-19 (2)
- Charm physics (2)
- NASH (2)
- Pb–Pb collisions (2)
- Single electrons (2)
- antiviral therapy (2)
- 2-deoxy-d-glucose (1)
- 900 GeV (1)
- ACE inhibitor (1)
- ACLF (1)
- ALICE detector (1)
- AT1 receptor antagonist (1)
- Anti-nuclei (1)
- Breast cancer (1)
- CD47 (1)
- CVID (1)
- Cancer detection and diagnosis (1)
- Cell-to-Cell Spread (1)
- Cellular (1)
- Centrality Class (1)
- Centrality Selection (1)
- Comparison with QCD (1)
- Conservation biogeography (1)
- Cytoskeletal proteins (1)
- DNA mismatch repair (1)
- Electron-pion identification (1)
- Elliptic flow (1)
- European Society for Immunodeficiencies (ESID) (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Genetic causes of cancer (1)
- Genetic testing (1)
- Genetic wildlife monitoring (1)
- German PID-NET registry (1)
- HBT (1)
- Hadron production (1)
- Hair sampling (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- Histology (1)
- Human genetics (1)
- IAP (1)
- IgG substitution therapy (1)
- Inclusive spectra (1)
- Intensity interferometry (1)
- Invariant Mass Distribution (1)
- Ionisation energy loss (1)
- Jets (1)
- Lure sticks (1)
- MLH1 (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Monte Carlo (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- NAFLD (1)
- Neural network (1)
- Noninvasive genetic sampling (1)
- Nuclear modification factor (1)
- Oncology (1)
- Ovarian cancer (1)
- PID prevalence (1)
- PYTHIA (1)
- Particle correlations and fluctuations (1)
- Pb–Pb (1)
- Production Cross Section (1)
- Proton–proton (1)
- QCD (1)
- Quark gluon plasma (1)
- Rapidity Range (1)
- Relativistic heavy ion physics (1)
- Resolution Parameter (1)
- Roux-en-Y gastric bypass (1)
- SIRPalpha (1)
- SPTAN1 (1)
- SR-BI (1)
- SVR (1)
- Single muons (1)
- Systematic Uncertainty (1)
- TR (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Trigger (1)
- Xenon-based gas mixture (1)
- bacterial translocation (1)
- benfooxythiamine (1)
- cell barrier integrity (1)
- coronavirus (1)
- dE/dx (1)
- fibrosis (1)
- heavy ion experiments (1)
- hepatic stellate cells (1)
- hepatocellular cancer (1)
- in vitro models (1)
- inflammation (1)
- mini gastric bypass (1)
- one anastomosis gastric bypass (1)
- oxLDL (1)
- oxythiamine (1)
- pentose phosphate pathway (1)
- primary immunodeficiency (PID) (1)
- quark gluon plasma (1)
- registry for primary immunodeficiency (1)
- spectra (1)
- steatosis (1)
- weight loss (1)
- √sN N = 2.76 TeV (1)
- fibrogenesis (1)
Institute
Background: Identification of families at risk for ovarian cancer offers the opportunity to consider prophylactic surgery thus reducing ovarian cancer mortality. So far, identification of potentially affected families in Germany was solely performed via family history and numbers of affected family members with breast or ovarian cancer. However, neither the prevalence of deleterious variants in BRCA1/2 in ovarian cancer in Germany nor the reliability of family history as trigger for genetic counselling has ever been evaluated.
Methods: Prospective counseling and germline testing of consecutive patients with primary diagnosis or with platinum-sensitive relapse of an invasive epithelial ovarian cancer. Testing included 25 candidate and established risk genes. Among these 25 genes, 16 genes (ATM, BRCA1, BRCA2, CDH1, CHEK2, MLH1, MSH2, MSH6, NBN, PMS2, PTEN, PALB2, RAD51C, RAD51D, STK11, TP53) were defined as established cancer risk genes. A positive family history was defined as at least one relative with breast cancer or ovarian cancer or breast cancer in personal history.
Results: In total, we analyzed 523 patients: 281 patients with primary diagnosis of ovarian cancer and 242 patients with relapsed disease. Median age at primary diagnosis was 58 years (range 16–93) and 406 patients (77.6%) had a high-grade serous ovarian cancer. In total, 27.9% of the patients showed at least one deleterious variant in all 25 investigated genes and 26.4% in the defined 16 risk genes. Deleterious variants were most prevalent in the BRCA1 (15.5%), BRCA2 (5.5%), RAD51C (2.5%) and PALB2 (1.1%) genes. The prevalence of deleterious variants did not differ significantly between patients at primary diagnosis and relapse. The prevalence of deleterious variants in BRCA1/2 (and in all 16 risk genes) in patients <60 years was 30.2% (33.2%) versus 10.6% (18.9%) in patients ≥60 years. Family history was positive in 43% of all patients. Patients with a positive family history had a prevalence of deleterious variants of 31.6% (36.0%) versus 11.4% (17.6%) and histologic subtype of high grade serous ovarian cancer versus other showed a prevalence of deleterious variants of 23.2% (29.1%) and 10.2% (14.8%), respectively. Testing only for BRCA1/2 would miss in our series more than 5% of the patients with a deleterious variant in established risk genes.
Conclusions: 26.4% of all patients harbor at least one deleterious variant in established risk genes. The threshold of 10% mutation rate which is accepted for reimbursement by health care providers in Germany was observed in all subgroups analyzed and neither age at primary diagnosis nor histo-type or family history sufficiently enough could identify a subgroup not eligible for genetic counselling and testing. Genetic testing should therefore be offered to every patient with invasive epithelial ovarian cancer and limiting testing to BRCA1/2 seems to be not sufficient.
SARS-CoV-2 is causing the coronavirus disease 2019 (COVID-19) pandemic, for which effective pharmacological therapies are needed. SARS-CoV-2 induces a shift of the host cell metabolism towards glycolysis, and the glycolysis inhibitor 2-deoxy-d-glucose (2DG), which interferes with SARS-CoV-2 infection, is under development for the treatment of COVID-19 patients. The glycolytic pathway generates intermediates that supply the non-oxidative branch of the pentose phosphate pathway (PPP). In this study, the analysis of proteomics data indicated increased transketolase (TKT) levels in SARS-CoV-2-infected cells, suggesting that a role is played by the non-oxidative PPP. In agreement, the TKT inhibitor benfooxythiamine (BOT) inhibited SARS-CoV-2 replication and increased the anti-SARS-CoV-2 activity of 2DG. In conclusion, SARS-CoV-2 infection is associated with changes in the regulation of the PPP. The TKT inhibitor BOT inhibited SARS-CoV-2 replication and increased the activity of the glycolysis inhibitor 2DG. Notably, metabolic drugs like BOT and 2DG may also interfere with COVID-19-associated immunopathology by modifying the metabolism of immune cells in addition to inhibiting SARS-CoV-2 replication. Hence, they may improve COVID-19 therapy outcomes by exerting antiviral and immunomodulatory effects.